Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-11-22

Clinical Trial Update: SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating SU11248 as consolidation after response to taxanes in metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SU11248 (sunitinib malate)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED